missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human KANK2 (aa 568-684) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (91%), Rat (91%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-53357 (PA5-53357. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a member of the KN motif and ankyrin repeat domains (KANK) family of proteins, which play a role in cytoskeletal formation by regulating actin polymerization. The encoded protein functions in the sequestration of steroid receptor coactivators and possibly other proteins. Mutations in this gene are associated with impaired kidney podocyte function and nephrotic syndrome, and keratoderma and woolly hair.
Specifications
Specifications
| Accession Number | Q63ZY3 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 25959 |
| Name | Human KANK2 (aa 568-684) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AI504612; ANKRD25; ankyrin repeat domain 25; ankyrin repeat domain-containing protein 25; BC010245; Kank2; KIAA1518; kidney ankyrin repeat-containing protein 2; KN motif and ankyrin repeat domain-containing protein 2; KN motif and ankyrin repeat domains 2; matrix-remodeling-associated protein 3; MXRA3; PPKWH; RGD1563532; SIP; SRC-1-interacting protein; SRC1-interacting protein; SRC-interacting protein |
| Common Name | KANK2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction